E1	Procedure:T1 Name:T2 Temporality:E38
E3	Condition:T3 Name:T4
E5	Procedure:T5 Name:T6 Temporality:E54
E7	Condition:T7 Name:T8
E8	Eq-Comparison:T22 Operator:T9 Value:T17
E9	Eq-Comparison:T23 Operator:T10 Temporal-Unit:T14 Value:T18
E10	Eq-Comparison:T24 Operator:T11 Temporal-Unit:T15 Value:T19
E11	Eq-Comparison:T25 Operator:T12 Value:T20 Unit:T67
E12	Eq-Comparison:T26 Operator:T13 Temporal-Unit:T16 Value:T21
E2	Condition:T27 Name:T28 Severity:T36
E4	Condition:T29 Name:T30
E13	Modifier:T33 Modifies:E2
E14	Modifier:T34 Modifies:E2
E15	Or:T35 Arg:E14 Arg2:E13
E16	Procedure:T37 Name:T38
E17	Procedure:T39 Name:T40 Temporality:E18 Minimum-Count:E8
E18	Eq-Comparison:T41 Temporal-Period:T42
E19	Modifier:T43 Modifies:E1
E20	Condition:T44 Name:T48
E21	Condition:T45 Name:T50
E22	Condition:T46 Name:T49
E23	Condition:T47 Name:T51
E24	Or:T52 Arg:E20 Arg2:E21
E25	Procedure:T53 Name:T54 Temporality:E39
E26	Procedure:T55 Temporality:E42
E27	Drug:T57 Name:T58
E28	Drug:T59 Name:T60
E30	Drug:T63
E31	Modifier:T65 Modifies:E30
E32	Study:T66 Study-Of:E49
E33	Procedure:T68
E34	Temporal-Connection:T69 Arg:E5 Arg2:E56
E35	Drug:T70 Temporality:E56
E6	Modifier:T31
E36	Modifier:T32 Modifies:T30
E37	Or:T72 Arg:E6 Arg2:E36
E38	Eq-Comparison:T73 Temporal-Recency:T74
E39	Eq-Comparison:T75 Temporal-Recency:T76
E40	Assertion:T77 Asserted:E25
E41	Temporal-Connection:T78 Arg:E9 Arg2:E39
E42	Eq-Comparison:T79 Temporal-Period:T80
E43	Modifier:T56 Modifies:T58
E44	Study:T81 Study-Of:E29
E45	Other:T82 Is-Other:E44
E29	Procedure:T61 Temporality:E10
E46	Drug:T62
E47	Eq-Comparison:T83 Temporal-Recency:T84
E48	Temporal-Connection:T85 Arg:E10 Arg2:E47
E49	Drug:T86 Temporality:E47
E50	Condition:T64 Name:T87
E51	Assertion:T88 Asserted:E7 Asserted2:E3
E52	Assertion:T89 Asserted:E33
E53	And:T90 Arg:E3 Arg2:E52
E54	Eq-Comparison:T91 Temporal-Period:T92
E55	Or:T93 Arg:E33 Arg2:E5
E56	Eq-Comparison:T71 Temporal-Recency:T94
T1	Procedure 346 323	chemotherapy regimen
T2	Procedure-Name 346 323	chemotherapy regimen
T3	Condition 834 779	pleural effusion
T4	Condition-Name 834 779	pleural effusion
T5	Procedure 898 841	ascites drainage
T6	Procedure-Name 898 841	ascites drainage
T7	Condition 815 761	cancer ascites
T8	Condition-Name 815 761	cancer ascites
T9	Eq-Operator 187 176	≥
T10	Eq-Operator 410 385	≤
T11	Eq-Operator 619 580	within
T12	Eq-Operator 667 624	<
T13	Eq-Operator 905 848	within
T14	Eq-Temporal-Unit 419 392	weeks
T15	Eq-Temporal-Unit 628 588	weeks
T16	Eq-Temporal-Unit 915 857	months
T17	Eq-Value 190 177	2
T18	Eq-Value 413 386	8
T19	Eq-Value 622 582	4
T20	Eq-Value 670 626	5
T21	Eq-Value 908 850	2
T22	Eq-Comparison 190 177	≥2
T23	Eq-Comparison 419 392	≤8 weeks
T24	Eq-Comparison 628 588	within 4 weeks
T25	Eq-Comparison 695 649	(< 5 elimination half-lives
T26	Eq-Comparison 915 857	within 2 months
T27	Condition 104 98	cancer
T28	Condition-Name 104 98	cancer
T29	Condition 161 154	cancer
T30	Condition-Name 161 154	cancer
T33	Modifier 97 91	endometrioid ovarian
T34	Modifier 73 67	serous
T35	Or 76 70	or
T36	Severity 66 60	high-grade
T37	Procedure 43 39	Histologically
T38	Procedure-Name 43 39	Histologically
T39	Procedure 230 215	platinum-containing regimens
T40	Procedure-Name 230 215	platinum-containing regimens
T41	Eq-Comparison 199 186	previous
T42	Eq-Temporal-Period 199 186	previous
T43	Modifier 325 302	platinum-based
T44	Condition 255 238	Complete response
T45	Condition 282 263	partial response
T46	Condition 260 242	CR
T47	Condition 287 267	PR
T48	Condition-Name 255 238	Complete response
T49	Condition-Name 260 242	CR
T50	Condition-Name 282 263	partial response
T51	Condition-Name 287 267	PR
T52	Or 265 246	or
T53	Procedure 447 420	platinum
T54	Procedure-Name 447 420	platinum
T55	Procedure 492 461	treatment
T57	Drug 532 497	poly (ADP-ribose) polymerase
T58	Drug-Name 532 497	poly (ADP-ribose) polymerase
T59	Drug 539 503	PARP
T60	Drug-Name 539 503	PARP
T63	Drug 752 704	drugs
T65	Modifier 732 686	molecular targeted
T66	Study 708 662	study
T67	Eq-Unit 695 649	half-lives
T68	Procedure 857 801	drainage
T69	Temporal-Connection 924 866	prior to
T70	Drug 949 891	administration
T31	Modifier 135 128	primary peritoneal
T32	Modifier 154 147	fallopian tube
T72	Or 139 132	and
T73	Eq-Comparison 308 287	last
T74	Eq-Temporal-Recency 308 287	last
T75	Eq-Comparison 430 403	last
T76	Eq-Temporal-Recency 430 403	last
T77	Assertion 394 369	Ability to
T78	Temporal-Connection 425 398	after
T79	Eq-Comparison 482 451	Prior
T80	Eq-Temporal-Period 482 451	Prior
T56	Modifier 551 514	inhibitor
T81	Study 597 558	study
T82	Other 591 552	other
T61	Procedure 612 573	treatment
T62	Drug 602 563	drug
T83	Eq-Comparison 647 607	first
T84	Eq-Temporal-Recency 647 607	first
T85	Temporal-Connection 637 597	prior to
T86	Drug 713 667	drug
T64	Condition 746 698	cancer
T87	Condition-Name 746 698	cancer
T88	Assertion 797 743	symptoms
T89	Assertion 845 789	need
T90	And 840 784	who
T91	Eq-Comparison 881 824	undergone
T92	Eq-Temporal-Period 881 824	undergone
T93	Or 862 805	or
T71	Eq-Comparison 934 876	first
T94	Eq-Temporal-Recency 934 876	first
A1	Eq-Operator-Value T9 GTEQ
A2	Eq-Operator-Value T10 LTEQ
A3	Eq-Operator-Value T11 LTEQ
A4	Eq-Operator-Value T12 LT
A5	Eq-Operator-Value T13 LTEQ
A6	Eq-Temporal-Unit-Value T14 week
A7	Eq-Temporal-Unit-Value T15 week
A8	Eq-Temporal-Unit-Value T16 month
A9	Severity-Value T36 severe
A11	Eq-Temporal-Period-Value T42 past
A12	Temporal-Connection-Type-Value E34 before
A10	Eq-Temporal-Recency-Value T74 most-recent-time
A13	Eq-Temporal-Recency-Value T76 most-recent-time
A14	Assertion-Type-Value E40 hypothetical
A15	Temporal-Connection-Type-Value E41 after
A16	Eq-Temporal-Period-Value T80 past
A17	Eq-Temporal-Recency-Value T84 first-time
A18	Temporal-Connection-Type-Value E48 before
A19	Assertion-Type-Value E51 possible
A20	Assertion-Type-Value E52 hypothetical
A21	Eq-Temporal-Period-Value T92 past
A22	Eq-Temporal-Recency-Value T94 first-time
R2	Example-Of Arg1:E4 Arg2:E2
R3	Found-By Arg1:E2 Arg2:E16
R4	Abbrev-Of Arg1:E22 Arg2:E20
R5	Abbrev-Of Arg1:E23 Arg2:E21
R6	Using Arg1:E21 Arg2:E1
R7	Using Arg1:E20 Arg2:E1
R8	Using Arg1:E26 Arg2:E27
R9	Abbrev-Of Arg1:E28 Arg2:E27
R1	Using Arg1:E29 Arg2:E46
R10	Equivalent-To Arg1:E11 Arg2:E47
R11	Treatment-For Arg1:E30 Arg2:E50
R12	Example-Of Arg1:E30 Arg2:E49